21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 14.11.2026 Expectation: 3500 pips
Sell Bitcoin with $75,000 in view
Yesterday at 08:47 AM 19
Period: 14.11.2026 Expectation: 150 pips
Go short on SPX down to $7,500
Yesterday at 06:47 AM 30
Brent sell
Period: 29.11.2026 Expectation: 450 pips
Brent crude sell-off targets $105
29 October 2026 21
Period: 12.11.2026 Expectation: 28000 pips
Go long on NVIDIA stock up to $243
29 October 2026 25
Period: 28.11.2026 Expectation: 130 pips
Invest in SPX with 7,850 in view
28 October 2026 37
Period: 28.11.2026 Expectation: 4200 pips
Selling EURUSD down to 1.07000
28 October 2026 53
Go to forecasts